To counter the current unmet needs of the market and to provide better treatment options, various research studies have focused on developing therapeutic treatments for Biliary Tract Cancers. With the continuous efforts in research and development and the involvement of key players such as Agios Pharmaceuticals, Bayer, Basilea Pharmaceutica, Delcath Systems, Hoffmann-La Roche, Incyte Corporation, Janssen Research & Development, Loxo Oncology, QED Therapeutics, and others, the Biliary Tract Cancers treatment scenario is expected to improve in the upcoming years.
DelveInsight’s “Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Biliary Tract Cancers market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Biliary Tract Cancers market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Biliary Tract Cancers: An Overview
Biliary Tract Cancer (BTC), also known as Cholangiocarcinoma (CCA), is a rare and heterogeneous malignant neoplasm with epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct, i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder. Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET, and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.
It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based on differences in their tumor biology and management.
Biliary Tract Cancers Market Key Facts
In 2021, the total Biliary Tract Cancer market size was USD 553 million, which is expected to rise during the study period (2019–2032).
The total Biliary Tract Cancer market size by therapies for early-stage disease in the year 2021 was USD 44.84 million.
The total market size of Biliary Tract Cancer in the United States accounted for USD 237 million in 2021, which is expected to rise during the study period (2019–2032).
In EU5, the total market size of Biliary Tract Cancer was USD 163 million in 2021.
In Japan, the total market size of Biliary Tract Cancer was USD 153 million in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Biliary Tract Cancers market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Biliary Tract Cancers market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Biliary Tract Cancers Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Biliary Tract Cancers Epidemiology, Segmented as –
Diagnosed incident Cases of Cholangiocarcinoma (CCA) (2019–2032)
Type-Specific Diagnosed Incident cases of Cholangiocarcinoma (CCA) (2019–2032)
Stage-Specific Diagnosed Incident Cases of Intrahepatic CCA (2019–2032)
Stage-Specific Diagnosed Incident Cases of Extrahepatic CCA (2019–2032)
Age-Specific Diagnosed Incident Cases of CCA (2019–2032)
Gender-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) (2019–2032)
Biomarker-Specific Diagnosed Incident Cases of ICCA (2019–2032)
Biomarker-Specific Diagnosed Incident Cases of ECCA (2019–2032)
Biliary Tract Cancers Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Biliary Tract Cancers market or expected to be launched during the study period. The analysis covers the Biliary Tract Cancers market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Tract Cancers pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Biliary Tract Cancers Market Will Evolve and Grow by 2032 @
Biliary Tract Cancers Therapeutics Analysis
In the near future, a personalized treatment approach targeting FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA, or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years by optimizing the outcomes of patients with this aggressive malignancy
Several major pharma and biotech companies are developing therapies for Asthma. Currently, AstraZeneca is leading the therapeutic market with its biliary tract cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Biliary Tract Cancers Therapeutics Market Include:
Adherex Technologies, Inc., Agios Pharmaceuticals, AstraZeneca, Basilea Pharmaceutica, Bayer, BeiGene, BioNTech SE, Black Diamond Therapeutics, Inc., Chia Tai Tianqing Pharmaceutical Group, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Delcath Systems, DualityBio Inc., Eisai, Eli Lilly and Company, Genentech, Genentech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Handok Inc., Hoffmann-La Roch, Incyte Corporation, InnoPharmax Inc., Jiangsu HengRui Medicine Co., Ltd., Leap Therapeutics, Inc., Lee’s Pharmaceutical Limited, Loxo Oncology, Medicenna Therapeutics, Inc., Merck Sharp & Dohme Corp., National Cancer Institute (NCI), QED Therapeutics, RaND Biosciences, RemeGen Co., Ltd., Roche, Servier Pharmaceuticals, Shanghai Miracogen Inc., Silverback Therapeutics, Sorrento Therapeutics, Inc., Taiho Oncology, Inc., TransThera Sciences (Nanjing), Zai Lab (Shanghai) Co., Ltd., Zymeworks Inc., and many others.
Biliary Tract Cancers Emerging and Marketed Drugs Covered in the Report Include:
MRG 002: Miracogen
AZD5305: Astra Zeneca
Ramucirumab: Eli Lilly and Company
Ivosidenib: Agios Pharmaceuticals
Pemigatinib: Incyte Corporation
Infigratinib: QED Therapeutics
Melphalan Hydrochloride: Delcath Systems
Larotrectinib: Loxo Oncology
Entrectinib: Hoffmann-La Roche
Derazantinib: Basilea Pharmaceutica
Erdafitinib: Janssen Research & Development
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Biliary Tract Cancers Competitive Intelligence Analysis
4. Biliary Tract Cancers Market Overview at a Glance
5. Biliary Tract Cancers Disease Background and Overview
6. Biliary Tract Cancers Patient Journey
7. Biliary Tract Cancers Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Biliary Tract Cancers Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Tract Cancers Unmet Needs
10. Key Endpoints of Biliary Tract Cancers Treatment
11. Biliary Tract Cancers Marketed Products
12. Biliary Tract Cancers Emerging Drugs and Latest Therapeutic Advances
13. Biliary Tract Cancers Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Tract Cancers Market Outlook (In US, EU5, and Japan)
16. Biliary Tract Cancers Access and Reimbursement Overview
17. KOL Views on the Biliary Tract Cancers Market
18. Biliary Tract Cancers Market Drivers
19. Biliary Tract Cancers Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Strategies
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States